Form 4: American Oncology Network CEO Todd Schonherz Receives 300,000 Shares of Class A Common Stock

Todd Schonherz, CEO of American Oncology Network, Inc., reports the acquisition of 300,000 shares of Class A Common Stock on July 16, 2024, as part of his compensation.

Summary

• Todd Schonherz, the CEO of American Oncology Network, Inc. (AONC), filed a Form 4 on July 18, 2024, reporting a transaction that occurred on July 16, 2024.
• He acquired 300,000 shares of Class A Common Stock as compensation for his role as CEO.
• Of these shares, 195,000 will vest over four years based on a time-based schedule, and 105,000 will vest based on a performance-based schedule.
• Both vesting schedules will accelerate upon a change in control.
• Schonherz also indirectly owns 869,459 shares of Class B Common Stock through the Schonherz Family Trust.
• He has granted a Limited Power of Attorney to Erica Mallon, Stephen Spivey, Ashley Knox, and Greg Imbrogno for Section 16 reporting obligations.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The stock grant is a standard practice and aligns the CEO's interests with shareholders. The vesting schedule incentivizes performance.

Positives

• The grant of shares to the CEO aligns his interests with those of the shareholders.
• The vesting schedule, including performance-based vesting, incentivizes the CEO to improve company performance.
• Acceleration of vesting upon a change in control may make the company more attractive to potential acquirers.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule suggests a multi-year commitment from the CEO.

Industry Context

This type of equity compensation is common for CEOs in publicly traded companies to align their interests with shareholders and incentivize performance.

Comparison to Industry Standards

• Equity compensation for CEOs in the oncology sector is a common practice.
• Comparable companies such as Varian Medical Systems (now part of Siemens Healthineers) and Accuray Incorporated also utilize stock grants and options as part of their executive compensation packages.
• The vesting schedules and performance-based metrics are generally aligned with industry standards to incentivize long-term value creation.

Stakeholder Impact

• Shareholders: The stock grant aligns the CEO's interests with those of the shareholders.
• Employees: The CEO's incentivization may lead to improved company performance, benefiting employees.
• Potential Acquirers: The acceleration of vesting upon a change in control may make the company more attractive to potential acquirers.

Key Dates

Keywords

Form 4, AONC, American Oncology Network, Todd Schonherz, CEO, stock grant, Class A Common Stock, beneficial ownership, Section 16, vesting schedule